Is DaliRasen available in China?

Daridorexant is a new dual orexin receptor antagonist (DORA drug), mainly used to treat chronic insomnia. It helps patients fall asleep faster and stay asleep longer by blocking receptors for orexin A and B neurotransmitters that promote wakefulness. As a new insomnia drug that has received widespread attention in recent years, Dalilaysan has been approved for marketing in many countries and is considered to have fewer side effects and less dependence than traditional sleeping pills. However, the drug has not yet been officially launched in mainland China.

As of2025, DaliRasen has not yet received marketing approval from China’s National Medical Products Administration (NMPA), so it cannot be purchased directly in domestic hospitals and pharmacies. For patients who really need medicine, they usually need to purchase it through overseas medical institutions, international pharmacies, or overseas purchasing agents. Although drugs can be obtained in this way, there are certain risks in terms of channels, quality and legality. It is recommended that patients must obtain them through formal institutions and use them under the guidance of professional doctors.

In foreign markets, the original drug of Dali Rasen has been launched by European pharmaceutical companies. The price of the European version of the original drug is about more than 2,000 yuan per box. The prescription indications of this drug in European and American countries are mainly concentrated on patients with long-term insomnia, especially middle-aged and elderly people who have difficulty falling asleep and maintaining sleep. Due to its stable efficacy and mild side effects, dalirasin is clinically regarded as a potential substitute for traditional benzodiazepines. At present, there are no generic drugs of DaliRaxon on the market in the world, so the choices are relatively limited.

Generally speaking, DaliRasen has not yet been launched in China and cannot be purchased through regular channels. If the drug is needed, it is recommended that patients obtain it through regular overseas channels and consult a professional doctor for individualized evaluation. With the expansion of the application scope of this drug in the international market, it is expected to be introduced into the Chinese market in the future and provide new treatment options for more patients with insomnia. For patients with severe or long-term insomnia, before considering Dalilera, they can first use local doctors to evaluate whether there is room for optimization of existing treatment options.

Reference materials：https://www.quviviq.com/